Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Research Biomedicals Extends Life Tech License

NEW YORK (GenomeWeb News) – Peptide and antibody maker Cambridge Research Biochemicals has extended a license agreement with Life Technologies that enables it to use the company's Molecular Probes line of dyes, CRB said today.

The extension of the agreement, originally formed in 2007, extends CRB's license to offer dye-labeled primary antibodies as well as peptides, the Billingham, UK-based firm said.

The extension of the non-exclusive license enables CRB to offer custom primary antibodies using the Molecular Probes fluorescent dye range — including the Alexa Fluor, BODIPY, Oregon Green, and Texas Red fluorophores — to its medical research and drug discovery customers.

Financial terms of the agreement were not released.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.